Enrollment of the Ph 1/2 OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer completed September 28, 2022
Applications Submitted For Rubraca® Label Expansion In The US And EU As 1L Maintenance Treatment In Advanced Ovarian Cancer Patients September 28, 2022
Oncologic Drugs Advisory Committee to review Zejula overall survival data from the NOVA Ph 3 trial in recurrent ovarian cancer September 28, 2022
Lynparza approved in China as 1L maintenance treatment with bevacizumab for HRD+ve advanced ovarian cancer September 28, 2022
Long-term data from the Ph 3 PRIMA study showed Zejula (niraparib) maintaining a sustained and clinically meaningful PFS benefit in 1L ovarian cancer patients September 13, 2022
Lynparza +/- bevacizumab demonstrates clinically meaningful survival benefit in 1L advanced ovarian cancer across PAOLA-1 and SOLO-1 Ph 3 trials September 13, 2022
Updated Findings from the Ph 2 SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer presented September 13, 2022
Patient-Reported Outcomes with Mirvetuximab vs Chemo in FORWARD I Study Reinforces Differentiated Tolerability Profile September 13, 2022
Rubraca® (Rucaparib) As 1L Maintenance Treatment Improves PFS In Women With Advanced Ovarian Cancer Across Disease Risk Subgroups September 13, 2022
SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer June 14, 2022
Modi-1 Ph 1/2 trial open for recruitment in patients with TNBC, ovarian cancer, head and neck cancer, and RCC April 12, 2022
Incyclix Bio Announces $30M Series B Financing to Support Clinical Development of INX-315 April 1, 2022
